NCT00674479 - INCB018424 in Patients With Advanced Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2008

Primary Completion Date

March 23, 2017

Study Completion Date

March 23, 2017

Conditions

Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaMyelodysplastic SyndromeChronic Myelogenous Leukemia

Interventions

DRUG

INCB018424

Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston